Raymond James Financial Services Advisors’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Raymond James Financial Services Advisors’s Portfolio STAB Stock Details STAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-102,250	Closed	-$13K	–	3421
2022 Q3	$13K	Sell	102,250 -10,000	-9%	-$2.11K	﹤0.01%	3197
2022 Q2	$32K	Hold	112,250	–	–	﹤0.01%	3127
2022 Q1	$35K	Buy	112,250 +82,391	+276%	+$88.1K	﹤0.01%	3222
2021 Q4	$69K	Buy	29,859 +17,609	+144%	+$52K	﹤0.01%	3157
2021 Q3	$28K	Buy	+12,250	New	+$46.4K	﹤0.01%	3224

Other funds holding STAB

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Raymond James Financial Services Advisors's STAB Position: Q4 2022 in Review

Raymond James Financial Services Advisors sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q4 2022, closing a stake of 102,250 shares — an estimated $13K sold.

Raymond James Financial Services Advisors first reported a position in STAB in Q3 2021 and held it in 5 quarters. The position peaked at $69K in Q4 2021. 29 funds tracked by Wall St. Rank hold STAB as of Q4 2022.

Raymond James Financial Services Advisors reported no remaining Statera Biopharma, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Raymond James Financial Services Advisors sold 102,250 Statera Biopharma, Inc. Common Stock shares in Q4 2022, an estimated $13K.
Raymond James Financial Services Advisors first reported a position in Statera Biopharma, Inc. Common Stock in Q3 2021 and held it in 5 quarters.
Raymond James Financial Services Advisors's Statera Biopharma, Inc. Common Stock position peaked at $69K in Q4 2021.
29 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q4 2022.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.